WEST JEFFERSON, North Carolina, July 2 /PRNewswire/ --

- Company's Nicotine Solution Provides Far Greater Psychoactive
Effects Than Tobacco Without The Negative Effects Of Carcinogens

Next Safety, Inc.'s pulmonary drug delivery device delivers extremely
high arterial levels of nicotine -- with effects felt less than ten seconds
after inhalation -- and provides higher psychoactive effects than cigarettes
or any other tobacco product on the market.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070615/CLF038LOGO )

It is expected that the device will substantially increase success rates
for those who wish to quit smoking due to its ability to accurately duplicate
the delivery of nicotine from tobacco smoke. Additionally, by delivering a
high percentage of nicotine to the bloodstream, the use of the device is
expected to cost less than 30 percent of the equivalent cost of cigarettes.

Next Safety, Inc. will package its proprietary pulmonary drug delivery
device into a handheld device that delivers nicotine more effectively than a
cigarette. (Photo: http://www.newscom.com/cgi-bin/prnh/20070702/CLM091)
Roughly the size of a pack of cigarettes, the unit will be used in much the
same way as current inhalers. Nicotine is supplied by replaceable cartridges
that contain nicotine and electronically stored information to ensure safe
dosing. Battery powered circuitry monitors the system to create and deliver
an aerosol to the lungs at the optimal point during inhalation. The aerosol
is delivered through a mouthpiece connected to the system by a flexible hose.

Initially, the unit will be provided to unregulated global markets with
availability in other areas following regulatory compliance. With 2006
tobacco sales of around US$218 billion in developed countries and more than
one billion smokers globally, Next Safety, Inc. anticipates production
volumes will reach more than one million units monthly in the first quarter
of 2008. Primary manufacturing capacity will be provided through
contract-manufacturing firms and a significant expansion of Next Safety's
West Jefferson, NC facility.

"North Carolina has long been known as 'Tobacco Road.' These days Tobacco
Road is known for technology. We believe that Next Safety's technology will
end the tobacco use epidemic," said C. Eric Hunter, CEO and founder of Next
Safety, Inc. "If I was a banker engaged in a private equity transaction
related to tobacco, a proposed deal in Europe comes to mind immediately,
these results would make me take a step back and evaluate the transaction in
light of this new information."

In addition to nicotine, Next Safety will soon launch drug delivery tests
utilizing its pulmonary drug delivery method and devices that will include
antibiotics (tobramycin), anti-emetics (promethazine), bronchodilators
(albuterol), and narcotics (morphine).

About Next Safety, Inc.

Next Safety is located in North Carolina, an area already known for
leadership in technology and medicine. The company has leveraged this
expertise to develop the worlds most advanced respirator technology and to
advance the field of pulmonary medicine. Next Safety's bPure8000(TM) line of
respirators provide higher protection against airborne viruses and fine
particulate air pollution than any other respirator available globally. Next
Safety now brings the same innovative approach to the science of pulmonary
drug delivery and nicotine replacement.

For more information about Next Safety, Inc. visit www.NextSafety.com

Web site: http://www.nextsafety.com